175 related articles for article (PubMed ID: 37843625)
21. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
22. MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma.
Lu F; Mu B; Jin G; Zhu L; Mu P
Oncol Res; 2022 May; 29(1):1-10. PubMed ID: 34937609
[TBL] [Abstract][Full Text] [Related]
23. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
24. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
Li D; Mei H; Pu J; Xiang X; Zhao X; Qu H; Huang K; Zheng L; Tong Q
Mol Cancer; 2015 Feb; 14():47. PubMed ID: 25889839
[TBL] [Abstract][Full Text] [Related]
25. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
26. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.
Yu Y; Chen F; Jin Y; Yang Y; Wang S; Zhang J; Chen C; Zeng Q; Han W; Wang H; Guo Y; Ni X
Acta Biochim Pol; 2020 Dec; 67(4):595-603. PubMed ID: 33326736
[TBL] [Abstract][Full Text] [Related]
27. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
Armstrong MB; Mody RJ; Ellis DC; Hill AB; Erichsen DA; Wechsler DS
Neoplasia; 2013 Dec; 15(12):1363-70. PubMed ID: 24403858
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of PIF1, a potential new target of MYCN, induces apoptosis and inhibits cell migration in neuroblastoma cells.
Chen B; Hua Z; Gong B; Tan X; Zhang S; Li Q; Chen Y; Zhang J; Li Z
Life Sci; 2020 Sep; 256():117820. PubMed ID: 32512012
[TBL] [Abstract][Full Text] [Related]
29. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
30. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
31. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
32. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of microRNA-143-3p induces apoptosis and suppresses proliferation, invasion, and migration of papillary thyroid carcinoma cells by targeting MSI2.
Wang ZL; Wang C; Liu W; Ai ZL
Exp Mol Pathol; 2020 Feb; 112():104342. PubMed ID: 31738908
[TBL] [Abstract][Full Text] [Related]
34. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
35. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.
Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848
[TBL] [Abstract][Full Text] [Related]
36. Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.
Gao J; Jung M; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ
Cancer Res; 2020 Sep; 80(17):3706-3718. PubMed ID: 32651259
[TBL] [Abstract][Full Text] [Related]
37. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
[TBL] [Abstract][Full Text] [Related]
38. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.
Li J; Peng J; Wu L; Shen X; Zhen X; Zhang Y; Ma H; Xu Y; Xiong Q; Zhu Q; Zhang P
J Biol Chem; 2023 Jul; 299(7):104856. PubMed ID: 37230388
[TBL] [Abstract][Full Text] [Related]
39. BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
Zhang X; Guo X; Zhuo R; Tao Y; Liang W; Yang R; Chen Y; Cao H; Jia S; Yu J; Liao X; Li X; Fang F; Li G; Wu D; Xu Y; Li Z; Pan J; Wang J
Biochem Biophys Res Commun; 2022 May; 604():63-69. PubMed ID: 35299072
[TBL] [Abstract][Full Text] [Related]
40. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]